PVR and neoplasm: On the other hand, CD155 also binds checkpoint inhibitory receptors, including T cell immunoreceptor with Ig and ITIM domains (TIGIT) and T cell-activated increased late expression (Tactile or CD96), thus counteracting DNAM-1 action in the late phases of tumor progression [19].